NeoGenomics, Inc. (NEO) News
Filter NEO News Items
NEO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NEO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest NEO News From Around the Web
Below are the latest news stories about NEOGENOMICS INC that investors may wish to consider to help them evaluate NEO as an investment opportunity.
NeoGenomics CEO Chris Smith to retireMore on NeoGenomics |
NeoGenomics Announces Chief Executive Officer SuccessionFT. MYERS, Fla., January 10, 2025--NeoGenomics' Chris Smith will retire as CEO and board member, effective April 1, 2025. Tony Zook will assume the role of CEO at that time. |
NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceFT. MYERS, Fla., January 06, 2025--NeoGenomics will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. |
NeoGenomics (NEO) Upgraded to Buy: Here's WhyNeoGenomics (NEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk MelanomaFT. MYERS, Fla., December 11, 2024--NeoGenomics' newly published study shows how ctDNA in MRD may enable earlier identification of disease recurrence for high-risk melanoma patients. |
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual MeetingFT. MYERS, Fla., December 09, 2024--NeoGenomics will present research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary CNS lymphoma at ASH |
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized TreatmentFT. MYERS, Fla., November 19, 2024--NeoGenomics will present four abstracts at the Association for Molecular Pathology 2024 Annual Meeting & Expo, November 19-23 (booth #830). |
Felicia Williams Joins NeoGenomics Board of DirectorsFORT MYERS, Fla., November 14, 2024--NeoGenomics announced the appointment of Felicia Williams to its Board of Directors. |
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare ConferenceFT. MYERS, Fla., November 08, 2024--NeoGenomics will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York City. |
NeoGenomics (NEO) Upgraded to Strong Buy: Here's What You Should KnowNeoGenomics (NEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |